Initiator Pharma receives an Intention to Grant notice in Europe for its Pipeline product candidate IPDP2015 for treatment of depression
January 30, 2018
Initiator Pharma announce that the company has received an Intention to Grant notice from the European Patent Office (“EPO”) for its patent application for the IPDP2015 product candidate. In essence, this means that the EPO intends to approve the company’s application.
The patent application for IPDP2015 product candidate for which the EPO has issued an Intention to Grant notice, refers to the company’s product candidate IPDP2015. An Intention to Grant notice means that the EPO intends to approve the company’s patent application but that a number of administrative steps remain before a final notice of approval can be issued.
The patent protects Initiator Pharmas IPDP2015 pipeline product candidate as a substance as well as its specific use for treatment of depression and a large number of associated neuropsychiatric disorders. Initiator Pharma seek to identify a collaboration partner to continue the preclinical development of IPDP2015.
The patent, when granted, provides protection of IPDP2015 in Europe until 2029. Initiator Pharma's corresponding patent in the USA was granted in 2014.
“The granting of a patent for our pipeline IPDP2015 product candidate is an important part of our efforts to build value in our portfolio”, Claus Olesen, CEO of Initiator Pharma, says. “We are very pleased that the examination of our application has been completed and that we have now taken a big step towards obtaining a patent also in this large and important market”.
For additional information about Initiator Pharma, please contact:
Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035 E-mail: email@example.com
Initiator Pharma is required to disclose the present information under the EU Market Abuse Regulation. The information was provided under the above contact person’s auspices, for publication on 30 January 2018
About Initiator Pharma
Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for patient suffering from Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond to the current market PDE5i medications like Viagra, Cialis and Levitra. Initiator Pharma is listed on AktieTorget, Sweden and has about 3400 shareholders. The company’s share is traded under the ticker INIT. Learn more at initiatorpharma.com